Archive for June, 2019
Cryoport: I View the Just Completed Equity Offering as a Major Positive (CYRX, Buy, $18.00)
Overview of Equity Offering Cryoport quickly and very successfully executed an equity offering after the close on June 19, 2019. It sold 3,750,000 shares at a price to investors of $17.00 per share. This was at a discount of about 9% from the closing price of $18.62. After underwriting discounts, Cryoport received $59.80 million which […]
Antares Pharma: Detailed Sales and Earnings Model Through 2021 (ATRS, $2.85, Buy)
Investment Thesis Recently, I have received a couple of sarcastic comments to the effect that this stock has gone nowhere for the last five or so years and you have consistently recommended it. Why don’t you just admit were wrong and move on. I share the frustration. I buy stocks that I recommend and hold […]
Antares Pharma: The Xyosted Launch Looks Like it will Meet or Beat Wall Street Expectations for 2019 (ATRS, Buy, $2.90)
Investment Thesis The cornerstone of my positive investment thesis for Antares is Xyosted, which was fully launched in January 2019. While it is very early, I believe that the prescription trends seen over the last four plus months strongly indicate that the launch will be a success. Xyosted is Antares’ second wholly owned and marketed […]
Northwest Biotherapeutics: Takeaways from Marnix Bosch’s Presentation at ASCO (NWBO, Buy, $0.27)
Overview Marnix Bosch, Chief Technical Officer of Northwest Biotherapeutics, discussed three broad topics at ASCO on Sunday June 2, 2019. Factors that will determine when we might see the all-important topline data from the phase 3 trial of DCVax-L in newly diagnosed glioblastoma multiforme (GBM). The hypothesized mode of action of DCVax Direct and plans […]